Recent Advances in Angiogenesis and ... - Bentham Science

More documents

Recommendations

Info

single proangiogenic protein. However, in apparent contrast with this view, experiments with neutralizing antibodies and other inhibitors demonstrated that blockade of vascular endothelial growth factor (VEGF) alone can substantially suppress tumor growth and angiogenesis in several models. Therefore, eventually other angiogenic proteins may be expressed by a tumor in which only VEGF is inhibited and give the clinical appearance of acquired “drug resistance”. A clinical challenge in antiangiogenesis is the finding of biological markers that help to identify subsets of patients more likely to respond to a given antiangiogenic therapy, as well as to determine optimal dosing of therapy, to detect early clinical benefit or emerging resistances and to decide whether to change therapy in secondline treatments. An ideal angiogenesis inhibitor should be orally bioavailable with acceptable short-term and long-term toxicity and have a clinically useful antitumor effect. Moreover, carefully constructed clinical trials with valid endpoints need to be executed. Finally, cancer genomics and proteomics are likely to identify novel tumor-specific endothelial targets and accelerate drug discovery. With the advent of specific and potent new agents, oncologists have a variety of direct and indirect antiangiogenic agents to choose from when designing therapy protocols. This book was undertaken to discuss the biological process and molecular mechanisms involved in angiogenesis and to discuss some agents that have shown to inhibit angiogenesis. I express my gratitude to all my colleagues who have contributed to this book. iii Domenico Ribatti University of Bari
CONTRIBUTORS Francesco Bertolini Unit Director,European Institute of Oncology, Milan, Italy Katiuscia Bonezzi Assistant, Tumor Angiogenesis Unit Department of Oncology, Mario Negri Institute for Pharmacological Research, Bergamo, Italy Paola Braidotti Assistant Professor, Department of Medicine, Surgery and Dentistry, University of Milan Medical School and “San Paolo” Hospital, Milan, Italy Federico Bussolino Full Professor, Institute for Cancer Research and Treatment, and Department of Oncological Sciences, University of Torino Medical School, Candiolo, Italy Anca Maria Cimpean Assistant Professor, Department of Histology and Molecular Pathology, “Victor Babes” University of Medicine and Pharmacy, Timisoara, Romania Enrico Crivellato Assistant Professor, Section of Anatomy, Department of Medical and Morphological Researches, University of Udine Medical School, Udine, Italy Maria Fico Postdoctoral Researcher, Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy Eberhard Gunsilius Assistant Professor of Medicine, Tumor Biology & Angiogenesis Laboratory, Department of Internal Medicine V, University of Innsbruck Medical School, Innsbruck, Austria Irene M. Ghobrial Assistant Professor in Medicine, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA Chyso Kanthou Tumour Microcirculation Group, Section of Oncology, School of Medicine & Biomedical Sciences, University of Sheffield, Sheffield, UK Robert S. Kerbel Full Professor, Sunnybrook Health Science Centre, Molecular and Cellular Biology, Department of Medical Biophysics, University of Toronto, Toronto, Canada Daria Leali Postdoctoral Researcher, Unit of General Pathology and Immunology,Department pf Biomedical Sciences and Biotechnology, University of Brescia Medical School, Brescia, Italy Sandra Liekens Postdoctoral Researcher, Department of Microbiology and Immunology, Rega Institute for Medical Research, Leuven, Belgium Giuseppe Mangialardi Postdoctoral Researcher, Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy Patrizia Mancuso Unit Vice Director, European Institute of Oncology, Milan, Italy Michele Moschetta Postdoctoral Researcher, Department of Biomedical Sciences and Human Oncology, University of Bari Medical School, Bari, Italy Antonella Naldini Associate Professor, Unit of Neuroimmunophysiology, Department of Physiology, University of Siena, Siena, Italy Fabio Pastorino Fellow, Fondazione Italiana per la Lotta al Neuroblastoma, “G. Gaslini” Children’s Hospital Genoa, Italy iv
Page 2 and 3: Recent Advances in Angiogenesis and
Page 4 and 5: FOREWORD It has been known for a ve
Page 8 and 9: v Vito Pistoia Head, Laboratory of
Page 10 and 11: 2 Recent Advances in Angiogenesis a
Page 12 and 13: 10 Recent Advances in Angiogenesis
Page 16 and 17: The Role of Mesenchymal Stem Cells
Page 22 and 23: Thymus and Angiogenesis Recent Adva
Page 32 and 33: Role of Thymidine Recent Advances i
Page 34 and 35: Role of Stromal Cells Recent Advanc
Page 40 and 41: Tumor Targeting with Transgenic End
Page 44 and 45: Tumor Vascular Disrupting Agents Re
Page 50 and 51: Tumour Vascular Disrupting Agents R
Page 52: Index Recent Advances in Angiogenes

Recent Advances in Angiogenesis and ... - Bentham Science

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?